The relentless march of antimicrobial resistance (AMR) has been described as a silent pandemic, a slow-motion catastrophe that threatens to unwind a century of medical progress. Yet, as the world edges closer to a post-antibiotic era, the pipeline for new drugs has all but dried up. The concern no one in the corridors of power is raising: the market itself has become the vector of this crisis.
Consider the numbers. The World Health Organisation has identified 32 antibiotics in clinical development, but only a handful target the most critical resistant pathogens. Of those, few will ever reach patients. The economics are brutally simple. Developing a new antibiotic costs upwards of $1 billion, with a high failure rate. When a drug finally gets approved, it is held in reserve to preserve its efficacy. Sales are meagre, often under $100 million a year. Meanwhile, a cancer drug can generate billions. The return on investment is a disincentive so stark that it has driven major pharmaceutical companies out of the field entirely. Pfizer, Novartis, AstraZeneca: all have scaled back or abandoned antibiotic research over the past decade.
This is not a failure of science, but of structural will. The pipeline is choked by a broken business model. Small biotech firms, which now carry the burden of early-stage antibiotic discovery, rely on venture capital and government grants. But even when they succeed, the path to market is a fiscal graveyard. Achaogen, a Californian biotech that developed a promising antibiotic for drug-resistant infections, filed for bankruptcy shortly after FDA approval. The drug, plazomicin, was deemed too valuable to use widely, yet too unprofitable to sustain the company.
The UK government has acknowledged the problem, launching a subscription-style payment model in 2023, where the NHS pays a fixed annual fee for access to certain antibiotics, regardless of usage. But the scheme covers only two drugs so far, and a single country cannot revive a global market. The G7 and G20 have issued statements, but action remains glacial. The PASTEUR Act in the US, designed to create similar incentives, has languished in Congress for years.
Meanwhile, the secondary consequences are already visible. Hospitals are forced to rely on last-resort antibiotics that were discovered decades ago. These drugs are increasingly ineffective. In 2019, bacterial infections resistant to antibiotics killed 1.27 million people globally. By 2050, the toll could reach 10 million annually, surpassing cancer. Routine surgeries, organ transplants, and chemotherapy will become life-threatening gambles.
Yet the silence from Westminster and Whitehall is deafening. There is no urgent cross-departmental task force, no ring-fenced funding for antibiotic development, no mandatory reduction targets for agricultural antibiotic use, which accounts for 70% of global consumption. The UK’s 20-year vision on AMR, published in 2013, promised a revitalised pipeline. Eleven years on, the pipeline is more desolate than ever.
Dr. Kieran Hand, a consultant pharmacist for antimicrobial resistance at University Hospital Southampton, put it bluntly: “We are effectively relying on the charity of a few small companies whose inventors are willing to work for poverty wages. The market has failed. It will take government intervention on the scale of the COVID-19 vaccine effort to fix this.”
